Interestingly, NaHS can also exert neuroprotective effects in models of peripheral nerve injury by reducing dopaminergic neuron loss in the midbrain through inhibition of IL-17–mediated pathways involving MLKL and tyrosine hydroxylase [29] and by modulating glutamatergic transmission via astrocytes and EAAT2 in the spinal cord [30]. The gene discussed is IL17A; the disease is peripheral nerve injury.